These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 19789309)

  • 1. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
    Ribas A; Comin-Anduix B; Chmielowski B; Jalil J; de la Rocha P; McCannel TA; Ochoa MT; Seja E; Villanueva A; Oseguera DK; Straatsma BR; Cochran AJ; Glaspy JA; Hui L; Marincola FM; Wang E; Economou JS; Gomez-Navarro J
    Clin Cancer Res; 2009 Oct; 15(19):6267-76. PubMed ID: 19789309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
    Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.
    Chodon T; Comin-Anduix B; Chmielowski B; Koya RC; Wu Z; Auerbach M; Ng C; Avramis E; Seja E; Villanueva A; McCannel TA; Ishiyama A; Czernin J; Radu CG; Wang X; Gjertson DW; Cochran AJ; Cornetta K; Wong DJ; Kaplan-Lefko P; Hamid O; Samlowski W; Cohen PA; Daniels GA; Mukherji B; Yang L; Zack JA; Kohn DB; Heath JR; Glaspy JA; Witte ON; Baltimore D; Economou JS; Ribas A
    Clin Cancer Res; 2014 May; 20(9):2457-65. PubMed ID: 24634374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.
    Ribas A; Glaspy JA; Lee Y; Dissette VB; Seja E; Vu HT; Tchekmedyian NS; Oseguera D; Comin-Anduix B; Wargo JA; Amarnani SN; McBride WH; Economou JS; Butterfield LH
    J Immunother; 2004; 27(5):354-67. PubMed ID: 15314544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.
    von Euw E; Chodon T; Attar N; Jalil J; Koya RC; Comin-Anduix B; Ribas A
    J Transl Med; 2009 May; 7():35. PubMed ID: 19457253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
    Panelli MC; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg SA; Marincola FM
    J Immunother; 2000; 23(4):487-98. PubMed ID: 10916759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
    Sanderson K; Scotland R; Lee P; Liu D; Groshen S; Snively J; Sian S; Nichol G; Davis T; Keler T; Yellin M; Weber J
    J Clin Oncol; 2005 Feb; 23(4):741-50. PubMed ID: 15613700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
    Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
    Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
    J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.
    Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R
    Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.
    Tarhini AA; Butterfield LH; Shuai Y; Gooding WE; Kalinski P; Kirkwood JM
    J Immunother; 2012; 35(9):702-10. PubMed ID: 23090079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.
    Oshita C; Takikawa M; Kume A; Miyata H; Ashizawa T; Iizuka A; Kiyohara Y; Yoshikawa S; Tanosaki R; Yamazaki N; Yamamoto A; Takesako K; Yamaguchi K; Akiyama Y
    Oncol Rep; 2012 Oct; 28(4):1131-8. PubMed ID: 22895835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
    Ribas A; Camacho LH; Lopez-Berestein G; Pavlov D; Bulanhagui CA; Millham R; Comin-Anduix B; Reuben JM; Seja E; Parker CA; Sharma A; Glaspy JA; Gomez-Navarro J
    J Clin Oncol; 2005 Dec; 23(35):8968-77. PubMed ID: 16204013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.
    Banchereau J; Ueno H; Dhodapkar M; Connolly J; Finholt JP; Klechevsky E; Blanck JP; Johnston DA; Palucka AK; Fay J
    J Immunother; 2005; 28(5):505-16. PubMed ID: 16113607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
    Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
    J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
    Hodi FS; Mihm MC; Soiffer RJ; Haluska FG; Butler M; Seiden MV; Davis T; Henry-Spires R; MacRae S; Willman A; Padera R; Jaklitsch MT; Shankar S; Chen TC; Korman A; Allison JP; Dranoff G
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4712-7. PubMed ID: 12682289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
    Ji Q; Gondek D; Hurwitz AA
    J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
    Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K
    Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.
    Carrasco J; Van Pel A; Neyns B; Lethé B; Brasseur F; Renkvist N; van der Bruggen P; van Baren N; Paulus R; Thielemans K; Boon T; Godelaine D
    J Immunol; 2008 Mar; 180(5):3585-93. PubMed ID: 18292586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.